CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in oncology Vol. 4; p. 385
Main Authors:	Callahan, Margaret K, Postow, Michael A, Wolchok, Jedd D
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 15-01-2015
Subjects:	CLTA-4 Immunotherapy ipilimumab Nivolumab Oncology PD-1 nivolumab PD-1 CLTA-4 immunotherapy ipilimumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Reviewed by: Amedeo Amedei, University of Florence, Italy; Carlos Alfaro, Clínica Universidad de Navarra, Spain Edited by: Michael Andrew Curran, University of Texas MD Anderson Cancer Center, USA This article was submitted to Tumor Immunity, a section of the journal Frontiers in Oncology.
ISSN:	2234-943X 2234-943X
DOI:	10.3389/fonc.2014.00385